AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06717854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transanal irrigation
Description: The enema is administered retrogradely via the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
Study NCT06717854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antegrade enema
Description: The enema is administered through the distal end of the ileocecal stoma, directed towards the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
Study NCT06731439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starting feeds within 6 hours of life
Description: Starting feeds within 6 hours of life
Study NCT06731439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard feeding protocol
Description: Starting feeds based on standard protocol as per primary team
Study NCT06731634 — intervention group
Intervention type: DEVICE
Intervention: Hand grip strength dynamometer, pinch strength dynamometer
Description: Both devices will be used to assign the strength of grip and pinch for both dominant and non dominant hands by using jamar hydraulic hand grip strength dynamometer and Jamar hydraulic pinch strength dynamometer
Study NCT06731634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Finkelstein test
Description: Finkelstein test which is used to diagnose the de quervain tenosynovitis and it will be used to assist the people with smartphone addiction
Study NCT06731400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA supplementation
Description: Six healthy individuals will be supplemented with fish oil contains omega 3 (EPA) for eight weeks, with blood samples collected before and after the intervention.
Study NCT06730581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule 60mg/m2/d
Description: 60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study NCT06730581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone capsule 75mg/m2
Description: 75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study NCT05892835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educative
Description: A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
Study NCT05390138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Sleep Apnea Self-management Support Programme (4S)
Description: The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
Study NCT05390138 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Hygiene Information (GH)
Description: The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
Study NCT06381037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How to improve your strengths and quality of life.
Description: The intervention program How to improve your strengths and quality of life consists of 8 individual sessions. The sessions take place weekly, so the total duration of the program is 8 weeks. Each session lasts approximately 1 hour. The sessions will be held both in person and online.~The sessions are:~* Session 1: Introduction to quality of life and personal strengths.~* Session 2: Self-fulfillment.~* Session 3: Pleasure.~* Session 4: Autonomy and control.~* Session 5: Family functioning and assertive communication.~* Session 6: Resilience.~* Session 7: Experiential acceptance.~* Session 8: Gratitude and closing of the workshop.
Study NCT06730581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule
Description: Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study NCT06731621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 2 dosing sessions 1 week apart, each about 6-8 hours duration~Psilocybin-assisted therapy (PAT), is a psychotherapeutic intervention in which the psychological effects of psilocybin play a significant role. PAT procedures typically involve psychological preparation prior to therapist-supported psilocybin dosing sessions. These sessions are used to establish a therapeutic relationship, inform participants about what to expect, and set expectations for the dosing session. During the psilocybin dosing session, trained therapists support the individual through their experience and psychological integration therapy occurs after the dosing experience. PAT has shown impressive antidepressant effects in people with TRD or severe MDD in at least six modern-era clinical trials (Andersen et al., 2021).
Study NCT06731309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Debridement
Description: A punch biopsy tool is positioned over the inflamed follicular unit, and a small circle of skin (4 to 8 mm in diameter) is excised. A firm twisting motion is necessary to ensure adequately deep excision.
Study NCT06731309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: Incision and Drainage is a minimally invasive surgical procedure often employed for the treatment of intensely painful, tense, and fluctuant abscesses that are too deep to drain spontaneously. After administration of a broad circumferential local anesthetic, a small linear incision is made using a standard scalpel blade. Digital pressure is applied to expel the fluid collection. Saline rinses can be used to flush out the remaining contents. This method offers instant pain relief, commonly performed in acute settings by dermatologists, emergency department physicians and general practitioners
Study NCT06731075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ORMD-0801 8 mg
Description: 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
Study NCT06731075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsule
Description: Placebo capsule
Study NCT06731075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule
Study NCT06731075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ORMD-0801 16 mg
Description: 2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
Study NCT06731348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restricted opioid prescribing
Description: Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.
Study NCT06731348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard opioid prescribing
Description: Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
Study NCT05342428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.
Study NCT05342428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.
Study NCT05428384 — intervention group
Intervention type: DEVICE
Intervention: MRI/ CardioMEMS comparison
Description: Each subject will have CardioMEMS readings paired with MRI scans
Study NCT03943927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Metoprolol Management
Description: CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient.
Study NCT05008809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
Study NCT05008809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
Study NCT05008809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.
Study NCT05008809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
Study NCT05409430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurothrombectomy
Description: The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion.
Study NCT04878458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy
Description: The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
Study NCT04878458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification with intraocular lens implantation combined with trabeculectomy
Description: The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
Study NCT06523439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro X100 edition (MagVenture, Skovlunde, Denmark)
Description: 10 daily sessions (50 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
Study NCT06523439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 edition (MagVenture, Skovlunde, Denmark)
Description: 5 daily sessions (25 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
Study NCT06446349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Description: identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
Study NCT05262868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
Study NCT05262868 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS
Description: The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
Study NCT05961345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: late mobilization
Description: Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
Study NCT06460415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomidulação
Description: The volunteers in the GFBM group will undergo 8 sessions of a combined red and infrared laser protocol with 4J of infrared power and 4J of red power. Being applied at 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) points in the intravaginal pelvic floor region. The MMO semiconductor laser device (GaA1As and InGaAlP) will be used with an area of the output laser beam at the NOZZLE of the laser pen of 3mm2 and wavelengths of 660nm (Red Laser) and 808nm (Infrared Laser) with a power of 100mW. The application will be carried out with the volunteers on a stretcher, in the supine position, gynecological position, with the knees and hips flexed and in abduction, feet supported on the stretcher.
Study NCT06460415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo control will be administered using the same device as the GFBM, but without any therapeutic dose delivery. Furthermore, the irradiated sites and irradiation time will be the same as PBMT. Volunteers will receive a total dose of 0 J in placebo mode. This treatment was also carried out in 8 sessions.
Study NCT04893070 — intervention group
Intervention type: OTHER
Intervention: Questionnaires COVID+
Description: * 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms~* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms
Study NCT04893070 — intervention group
Intervention type: OTHER
Intervention: Questionnaires COVID-
Description: * 1 questionnaire on quality of life at enrollment~* 1 questionnaire on quality of life 6 months after enrollment
Study NCT06078930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tongue imaging, tougue coating, saliva, and feces
Description: Tongue images, coating, saliva, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
Study NCT04948879 — intervention group
Intervention type: PROCEDURE
Intervention: Vascular resection/reconstruction
Description: The resection of a major blood vessel with or without reconstruction
Study NCT05921071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
Study NCT05921071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive 10 ml of normal saline 0.9% intravenously.
Study NCT05592080 — intervention group
Intervention type: RADIATION
Intervention: MRI
Description: MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.
Study NCT05581238 — intervention group
Intervention type: OTHER
Intervention: TRACK-TCT
Description: An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.
Study NCT05047796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Protocol
Description: The intervention protocol will consist of visceral osteopathic techniques and will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy.
Study NCT05047796 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Protocol
Description: The sham protocol will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy. The sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, without therapeutic intent
Study NCT05372887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Study NCT05372887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Study NCT05273086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention Group
Description: The intervention group will acquire skills to improve their quality of sleep such as:~* Acquisition of notions of chronobiology.~* Location of the nervous structures involved in biological rhythms.~* Awareness of the existence of three times that direct our biological rhythms, and of the need for them to be synchronized.~* Self-knowledge of the chronotype and the degree of adjustment of the three times.~* Knowledge of the variables that determine a good quality of sleep.~* Applications of chronobiology to the field of nursing. Recommendations for nurses and patients.~* Self-knowledge of the quality of sleep and the health status of the circadian system.
Study NCT05045911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Barbed-clips Suturing
Description: Endoscopic Barbed-clips Suturing
Study NCT06099431 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mandibular marginal resection and reconstruction
Description: Intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins were carried out around the teeth to be included in the resection. The osteotomy lines were marked using a long shank surgical tapered fissure bur. The osteotomies completed and the resected segment was removed.
Study NCT06099431 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: mandibular osteosynthesis a 2.3mm reconstruction bone plate
Description: a 2.3 mm reconstruction bone plate was then fit in place and fixed to both the proximal and distal segments
Study NCT05347290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rampart IC, M1128
Description: Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
Study NCT05347290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lead Apron and Ancillary Shield
Description: Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
Study NCT05347290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rampart IC, M1128 and Lead Apron
Description: Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
Study NCT06523543 — intervention group
Intervention type: PROCEDURE
Intervention: Inclusion (Visit 1 - Week 7-16)
Description: Extraction of cervico-vaginal sampling